DK3495352T3 - Krystalformer af en androgenreceptorantagonist, fremgangsmåde til fremstilling og anvendelse deraf - Google Patents
Krystalformer af en androgenreceptorantagonist, fremgangsmåde til fremstilling og anvendelse deraf Download PDFInfo
- Publication number
- DK3495352T3 DK3495352T3 DK17842980.9T DK17842980T DK3495352T3 DK 3495352 T3 DK3495352 T3 DK 3495352T3 DK 17842980 T DK17842980 T DK 17842980T DK 3495352 T3 DK3495352 T3 DK 3495352T3
- Authority
- DK
- Denmark
- Prior art keywords
- androgen
- antagonist
- reception
- manufacture
- crystal forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610737732 | 2016-08-26 | ||
| CN201610871736 | 2016-09-30 | ||
| CN201610876685 | 2016-10-08 | ||
| PCT/CN2017/099036 WO2018036558A1 (zh) | 2016-08-26 | 2017-08-25 | 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3495352T3 true DK3495352T3 (da) | 2021-05-03 |
Family
ID=61246439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17842980.9T DK3495352T3 (da) | 2016-08-26 | 2017-08-25 | Krystalformer af en androgenreceptorantagonist, fremgangsmåde til fremstilling og anvendelse deraf |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10815221B2 (da) |
| EP (1) | EP3495352B1 (da) |
| JP (1) | JP6716023B2 (da) |
| CN (1) | CN109641851B (da) |
| CY (1) | CY1124083T1 (da) |
| DK (1) | DK3495352T3 (da) |
| ES (1) | ES2869882T3 (da) |
| HR (1) | HRP20210667T1 (da) |
| HU (1) | HUE053958T2 (da) |
| LT (1) | LT3495352T (da) |
| PL (1) | PL3495352T3 (da) |
| PT (1) | PT3495352T (da) |
| RS (1) | RS61773B1 (da) |
| SI (1) | SI3495352T1 (da) |
| SM (1) | SMT202100251T1 (da) |
| WO (1) | WO2018036558A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3592732T3 (fi) * | 2017-03-07 | 2025-05-28 | Orion Corp | Kiteisen farmaseuttisen tuotteen valmistus |
| WO2019028689A1 (zh) * | 2017-08-09 | 2019-02-14 | 杭州领业医药科技有限公司 | Odm-201晶型及其制备方法和药物组合物 |
| JP2021515040A (ja) * | 2018-02-27 | 2021-06-17 | サンド・アクチエンゲゼルシヤフト | ダロルタミドの結晶形態ｉｉ |
| WO2020081837A1 (en) * | 2018-10-18 | 2020-04-23 | Gemphire Therapeutics Inc. | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor |
| WO2022036782A1 (zh) * | 2020-08-18 | 2022-02-24 | 拜耳消费者护理股份有限公司 | 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途 |
| MX2024009980A (es) | 2022-02-28 | 2024-08-26 | Quim Sintetica S A | Forma cristalina de darolutamida. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR078793A1 (es) * | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| ES2541295T3 (es) | 2011-04-21 | 2015-07-17 | Orion Corporation | Carboxamidas que modulan el receptor de andrógenos |
| DK3250554T3 (da) | 2015-01-30 | 2022-06-27 | Orion Corp | Carboxamidderivat og diastereomerer deraf i stabil, krystallinsk form |
| WO2019028689A1 (zh) * | 2017-08-09 | 2019-02-14 | 杭州领业医药科技有限公司 | Odm-201晶型及其制备方法和药物组合物 |
-
2017
- 2017-08-25 JP JP2019511530A patent/JP6716023B2/ja active Active
- 2017-08-25 RS RS20210521A patent/RS61773B1/sr unknown
- 2017-08-25 ES ES17842980T patent/ES2869882T3/es active Active
- 2017-08-25 EP EP17842980.9A patent/EP3495352B1/en active Active
- 2017-08-25 WO PCT/CN2017/099036 patent/WO2018036558A1/zh not_active Ceased
- 2017-08-25 LT LTEP17842980.9T patent/LT3495352T/lt unknown
- 2017-08-25 SM SM20210251T patent/SMT202100251T1/it unknown
- 2017-08-25 DK DK17842980.9T patent/DK3495352T3/da active
- 2017-08-25 US US16/328,249 patent/US10815221B2/en active Active
- 2017-08-25 PL PL17842980T patent/PL3495352T3/pl unknown
- 2017-08-25 HU HUE17842980A patent/HUE053958T2/hu unknown
- 2017-08-25 PT PT178429809T patent/PT3495352T/pt unknown
- 2017-08-25 HR HRP20210667TT patent/HRP20210667T1/hr unknown
- 2017-08-25 SI SI201730734T patent/SI3495352T1/sl unknown
- 2017-08-25 CN CN201780048143.1A patent/CN109641851B/zh active Active
-
2021
- 2021-04-27 CY CY20211100367T patent/CY1124083T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE053958T2 (hu) | 2021-08-30 |
| LT3495352T (lt) | 2021-06-10 |
| US20200239450A1 (en) | 2020-07-30 |
| PT3495352T (pt) | 2021-05-03 |
| EP3495352A4 (en) | 2019-06-12 |
| RS61773B1 (sr) | 2021-05-31 |
| HRP20210667T1 (hr) | 2021-05-28 |
| CY1124083T1 (el) | 2022-03-24 |
| EP3495352B1 (en) | 2021-01-27 |
| CN109641851B (zh) | 2022-09-02 |
| EP3495352A1 (en) | 2019-06-12 |
| CN109641851A (zh) | 2019-04-16 |
| JP2019526570A (ja) | 2019-09-19 |
| ES2869882T3 (es) | 2021-10-26 |
| WO2018036558A1 (zh) | 2018-03-01 |
| SI3495352T1 (sl) | 2021-08-31 |
| SMT202100251T1 (it) | 2021-05-07 |
| US10815221B2 (en) | 2020-10-27 |
| PL3495352T3 (pl) | 2021-08-02 |
| JP6716023B2 (ja) | 2020-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3526202T3 (da) | Forbindelser og fremgangsmåder til målrettet degradering af androgenreceptor | |
| DK3667980T3 (da) | Indikation og modtagelse af ressourceposition | |
| DK3185868T3 (da) | Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| DK3194184T3 (da) | Transmitteringsindretning og fremgangsmåde til trådløs transmission af målte parametre | |
| DK3152956T3 (da) | Systemer og metoder til kommunikation | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| DK3160470T3 (da) | Analoger af pridopidin, fremstilling og anvendelse heraf | |
| DK3365684T3 (da) | Fremgangsmåde til berigelse af cellefrie nukleosomer | |
| DK3495352T3 (da) | Krystalformer af en androgenreceptorantagonist, fremgangsmåde til fremstilling og anvendelse deraf | |
| DK3178324T3 (da) | Mikrobicid og fremgangsmåde til fremstilling af samme | |
| DK3470400T3 (da) | Krystallinske former af ozanimod og ozanimodhydrochlorid samtfremgangsmåder til fremstilling deraf | |
| DK3574135T3 (da) | Fremgangsmåde og formulering til fremstilling af ligninfibre | |
| DK3280710T3 (da) | Fremgangsmåde til fremstilling af androgenreceptorantagonister og mellemprodukter deraf | |
| DK3572062T3 (da) | Vandholdig kapsel og fremgangsmåde til fremstilling af vandholdig kapsel | |
| DK3630772T3 (da) | Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere | |
| DK3205653T3 (da) | Krystalform af bisulfat af jak-hæmmer og fremgangsmåde til fremstilling deraf | |
| DK3277742T3 (da) | Fluorescerende siloxanelastomer, fremgangsmåde til fremstilling af denne og anvendelsen | |
| DK3327969T3 (da) | Ny fremgangsmåde til trådløs overførsel af digital lyd | |
| DK3347342T3 (da) | Fremgangsmåde til fremstilling af biguanidin-salte og s-triaziner | |
| DK3452424T3 (da) | Fremgangsmåde og anlæg til fremstilling af cement | |
| DK3665133T3 (da) | Fremgangsmåde og anlæg til fremstilling af cement | |
| DK3359725T3 (da) | Indretning og fremgangsmåde til reorientering/orientering og justering af klæde | |
| DK3309149T3 (da) | 6-Brom-3-hydroxy-2-pyrazincarboxamid-krystal og fremgangsmåde til fremstilling af dette |